Angiotensin II does not affect endothelial tone in Type 1 diabetes-results of a double-blind placebo controlled trial

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

The researchers examined whether selective blockade of angiotensin II influences endothelial tone with particular reference to the nitric oxide/prostaglandin pathways in patients with Type 1 diabetes free from vascular complications.

Who Took Part

The abstract describes 30 patients taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Blinding on both sides kept the patients and researchers unaware of who received Angiotensin II.

Some patients received a placebo instead of Angiotensin II, giving a reference point.

What Was Measured

The subject headings attached to it are Acetylcholine, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Biphenyl Compounds, Cyclooxygenase Inhibitors, Diabetes Mellitus, Type 1 and Endothelium, Vascular.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Angiotensin II compound page, all human trials.